TP-003

<h2 id="see-also">See also</h2>
<ul><li><a href="/facts/Imidazopyridine/UNyM3oay">Imidazopyridine</a></li>
<li><a href="/facts/L-838,417/Ulm5QXbf">L-838,417</a></li>
<li><a href="/facts/Alpidem/EuMb4tm3">Alpidem</a></li></ul>

<h2 id="references">References</h2>

<ol>
<li id="fn:1"><p>Neumann E, Ralvenius WT, Acuña MA, Rudolph U, Zeilhofer HU (2018). "TP003 is a non-selective benzodiazepine site agonist that induces anxiolysis via α2GABAA receptors". Neuropharmacology. 143: 71–78. doi:10.1016/j.neuropharm.2018.09.026. PMID 30240781. S2CID 52313196. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li>
<li id="fn:2"><p>Rudolph U, Möhler H (2013-10-23). "GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism". Annual Review of Pharmacology and Toxicology. 54: 483–507. doi:10.1146/annurev-pharmtox-011613-135947. PMC 3997216. PMID 24160694. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997216" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997216</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li>
<li id="fn:3"><p>Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, et al. (Jun 2007). "Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands". Journal of Psychopharmacology. 21 (4): 384–91. doi:10.1177/0269881106067255. PMID 17092983. S2CID 34355306. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li>
</ol>

TP-003 open-in-new

TP-003